Roche Holding AG, of Basel, Switzerland, said its member company Genentech disclosed that the FDA granted breakthrough therapy designation to Rituxan (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.